The Fred Hutchinson/University of Washington Cancer Consortium (Consortium) brings together more than 450 members with research interests in basic, clinical and public health sciences related to cancer. The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration between the partner institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. Over the next grant period, the Consortium will seek to: (1) Continue its leadership in cellular immunotherapy, with the goal of making this therapeutic platform the standard of care for many malignancies; (2) Build on our outstanding strengths in cancer basic biology to increase collaborative translational research, including using genomic and epigenomic technologies to develop effective prognostic tests for solid tumor cancers, applying protein engineering to novel cancer therapeutics, and developing robust mouse models of cancer for rapid screening of drug response prior to therapeutic intervention; (3) Expand our pioneering efforts to reduce the global burden of cancer through translational research on infection-related malignancies, application of global disease surveillance data, and unique international partnerships in Africa (Uganda and South Africa) and more recently China to establish robust platforms for improving our understanding of the spectrum of cancer biology and disease worldwide; (4) Lead research that supports provision of efficient, effective and cost-effective cancer care through research in health economics, cancer outcomes and comparative effectiveness; and (5) Lead population-based research to uncover new insights into the link between obesity and cancer, and to reduce disparities in cancer risk, outcomes and access to care in underserved populations.

Public Health Relevance

There were an estimated 1.6 million new cases of cancer in the United States in 2013, and an estimated 580,000 deaths from the disease. Cancer is the second leading cause of the death in the U.S. The goal of the Fred Hutchinson/University of Washington Cancer Consortium is the elimination of cancer through more effective prevention, diagnosis, and treatment, deriving from fundamental insights into the biology of the disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-41
Application #
9001906
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-01-01
Project End
2019-12-31
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
41
Fiscal Year
2016
Total Cost
$9,561,228
Indirect Cost
$3,551,814
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hay, Kevin A; Turtle, Cameron J (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10:251-254
Davis, Ryan J; Gönen, Mehmet; Margineantu, Daciana H et al. (2018) Pan-cancer transcriptional signatures predictive of oncogenic mutations reveal that Fbw7 regulates cancer cell oxidative metabolism. Proc Natl Acad Sci U S A 115:5462-5467
Sillah, Arthur; Watson, Nathaniel F; Schwartz, Stephen M et al. (2018) Sleep apnea and subsequent cancer incidence. Cancer Causes Control 29:987-994
He, Qianchuan; Liu, Yang; Sun, Wei (2018) Statistical analysis of non-coding RNA data. Cancer Lett 417:161-167
Ginos, Bigina N R; Navarro, Sandi L; Schwarz, Yvonne et al. (2018) Circulating bile acids in healthy adults respond differently to a dietary pattern characterized by whole grains, legumes and fruits and vegetables compared to a diet high in refined grains and added sugars: A randomized, controlled, crossover feeding stud Metabolism 83:197-204
Sullivan, Kevin M; Kenerson, Heidi L; Pillarisetty, Venu G et al. (2018) Precision oncology in liver cancer. Ann Transl Med 6:285
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Ranola, John Michael O; Pearlman, Rachel; Hampel, Heather et al. (2018) Modified capture-recapture estimates of the number of families with Lynch syndrome in Central Ohio. Fam Cancer :
Dai, James Y; Liang, C Jason; LeBlanc, Michael et al. (2018) Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics 74:753-763

Showing the most recent 10 out of 1267 publications